FrancophonIA/ELRC3.0 huggingface dataset:
English: • That patients should be counselled that: they should consult a physician if they develop or experience worsening signs or symptoms of heart failure; they should immediately report to a physician any symptoms of potential liver injury; MULTAQ interacts with a number of medicines; if they consult other doctors they should inform them that they are taking MULTAQ; they should not take St John's Wort with MULTAQ; they should avoid grapefruit juice.
Danish: o de skal konsultere en læge hvis de udvikler tegn eller symptomer på forværring af hjerteinsufficiens; o de øjeblikkeligt skal melde alle symptomer på potentiel leverskade til en læge; o MULTAQ interagerer med adskillige lægemidler; o hvis de konsulterer andre læger, skal de informere om, at de tager MULTAQ; o de ikke må tage perikon, så længe de er i behandling med MULTAQ; o de skal undgå grapefrugtjuice.
English: • That MULTAQ must not be used in patients with unstable haemodynamic conditions including patients with symptoms of heart failure at rest or with minimal exertion (corresponding to NYHA class IV and unstable class III patients).
Danish: • At MULTAQ ikke må anvendes hos patienter i ustabil hæmodynamisk tilstand, inklusiv patienter med symptomer på hjerteinsufficiens under hvile eller minimal fysisk udfoldelse (svarende til NYHA klasse IV og ustabile klasse III-patienter).
English: If ALT levels are confirmed to be ≥3 × ULN after re-measurement, treatment with dronedarone should be withdrawn.
Danish: Hvis ALAT-niveauet bekræftes at være ≥3 x den øvre normalværdi, efter kontrolbestemmelse, skal dronedaron seponeres.
English: • As the MULTAQ Information Card does not include all warnings or contraindications, the SPC should be referred to prior to prescribing MULTAQ and also prior to prescribing additional drugs to a patient already taking MULTAQ.
Danish: • Da MULTAQ-informationskortet ikke indeholder alle advarsler og kontraindikationer, skal der henvises til produktresuméet for MULTAQ, før MULTAQ udskrives og før udskrivning af andre lægemidler til patienter, der får MULTAQ.
English: o potential torsades de pointes inducers including phenothiazines, cisapride, bepridil, tricyclic antidepressants, terfenadine and certain oral macrolides.
Danish: • Potentielle torsades de pointes-inducere såsom phenothiaziner, cisaprid, bepridil, tricykliske antidepressiva, terfenadin og visse orale makrolider.
English: • Use with caution: in association with digoxin, beta blockers, calcium antagonists, statins and vitamin K antagonists.
Danish: • Anvendes med forsigtighed: i kombination med digoxin, betablokkere, calciumantagonister, statiner og vitamin K-antagonister.
English: • Contraindication: o CYP3A inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir.
Danish: • CYP3A-inhibitorer såsom ketoconazol, itraconazol, voriconazol, posaconazol, telithromycin, clarithromycin, nefazodon og ritonavir.
English: • Not recommended/to be avoided: o grapefruit juice, o potent CYP3A4 inducers including rifampicin, phenobarbital, carbamazepine, phenytoin, St John's Wort o dabigatran.
Danish: • potente CYP3A4-induktorer såsom rifampicin, phenobarbital, carbamazepin, phenytoin, perikon.
English: Content Package size
Danish: Indhold Pakningsstø rrelse
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kinzalmono on 16 December 1998.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Kinzalmono den 16. december 1998.
English: The full EPAR for Kinzalmono can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Danish: Den fuldstændige EPAR for Kinzalmono findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Kinzalmono.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Kinzalmono.
English: A risk management plan has been developed to ensure that Kinzalmono is used as safely as possible.
Danish: Der er udarbejdet en risikostyringsplan for at sikre, at Kinzalmono anvendes så sikkert som muligt.
English: Other information about Kinzalmono
Danish: Andre oplysninger om Kinzalmono
English: Kinzalmono is a medicine that contains the active substance telmisartan.
Danish: Kinzalmono er et lægemiddel, som indeholder det aktive stof telmisartan.
English: Kinzalmono must not be used in women who are more than three months pregnant.
Danish: Kinzalmono må ikke anvendes til gravide, som er længere end tre måneder henne i graviditeten.
English: What measures are being taken to ensure the safe and effective use of Kinzalmono?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Kinzalmono?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kinzalmono.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om, hvordan Kinzalmono skal anvendes.
English: It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.
Danish: Desuden kan hjertet lettere pumpe blodet rundt, hvilket kan bidrage til at reducere risikoen for kardiovaskulære problemer i fremtiden.
English: The active substance in Kinzalmono, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Danish: Det aktive stof i Kinzalmono, telmisartan, er en "angiotensin II-receptorantagonist", hvilket betyder, at den blokerer virkningen af et hormon i kroppen, der kaldes angiotensin II.
English: The CHMP decided that Kinzalmono's benefits are greater than its risks and recommended that it be given marketing authorisation.
Danish: CHMP besluttede, at fordelene ved Kinzalmono opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
English: Kinzalmono is used to treat essential hypertension (high blood pressure) in adults.
Danish: Kinzalmono anvendes til behandling af essentiel hypertension (for højt blodtryk) hos voksne.
English: For more information about treatment with Kinzalmono, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Kinzalmono, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: The doctor should monitor the patient's blood pressure closely when starting Kinzalmono, and may decide to adjust the patient's blood pressure-lowering medication.
Danish: Lægen bør overvåge patientens blodtryk nøje, når behandlingen med Kinzalmono påbegyndes, og kan beslutte at justere patientens blodtrykssænkende medicin.
English: Hypotension may be more common in patients receiving Kinzalmono to prevent cardiovascular problems.
Danish: Hypotension kan forekomme oftere hos patienter, der får Kinzalmono for at forebygge kardiovaskulære problemer.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kinzalmono, including the appropriate precautions to be followed by healthcare professionals and patients.
Danish: På baggrund af denne er der anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Kinzalmono, herunder passende forholdsregler, som sundhedspersonale og patienter skal følge.
English: Kinzalmono was compared with ramipril (another medicine to prevent cardiovascular problems), and with the combination of both medicines.
Danish: Kinzalmono blev sammenlignet med ramipril (et andet lægemiddel til forebyggelse af kardiovaskulære problemer) og med kombinationen af begge lægemidler.
English: Various doses of Kinzalmono were compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine).
Danish: Forskellige doseringer af Kinzalmono blev sammenlignet med placebo (en virkningsløs behandling) og med andre lægemidler mod hypertension (atenolol, lisinopril, enalapril og amlodipin).
English: For the treatment of essential hypertension, the usual recommended dose of Kinzalmono is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Danish: Til behandling af essentiel hypertension er den sædvanlige anbefalede dosis af Kinzalmono 40 mg én gang dagligt, men visse patienter kan klare sig med 20 mg én gang dagligt.
English: Kinzalmono is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Danish: Kinzalmono anvendes også til at forebygge kardiovaskulære problemer (problemer med hjertet og blodkarrene) såsom hjerteanfald eller slagtilfælde.
English: Kinzalmono must not be used in people who have severe liver problems or bile problems.
Danish: Kinzalmono må ikke anvendes til personer, der har alvorlige leverproblemer eller galdeproblemer.
English: In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, Kinzalmono must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension).
Danish: Hos patienter med type 2-diabetes eller moderat eller alvorlig nyresygdom må Kinzalmono desuden ikke anvendes i kombination med lægemidler, der indeholder aliskiren (som også anvendes til behandling af essentiel hypertension).
English: For the treatment of essential hypertension, Kinzalmono has been studied in 2,647 patients who took Kinzalmono either alone or in combination with hydrochlorothiazide.
Danish: Kinzalmono er, til behandling af essentiel hypertension, blevet undersøgt hos 2 647 patienter, der fik Kinzalmono enten alene eller i kombination med hydrochlorothiazid.
English: For the prevention of cardiovascular problems, 80 mg Kinzalmono once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems.
Danish: Til forebyggelse af kardiovaskulære problemer er Kinzalmono 80 mg én gang dagligt blevet undersøgt i en hovedundersøgelse med deltagelse af knap 26 000 patienter i alderen 55 år eller derover, som havde hjerte- eller arteriesygdom, havde haft et slagtilfælde eller havde diabetes, og som havde stor risiko for kardiovaskulære problemer.
English: What is the risk associated with Kinzalmono?
Danish: Hvilken risiko er der forbundet med Kinzalmono?
English: Why has Kinzalmono been approved?
Danish: Hvorfor blev Kinzalmono godkendt?
English: In the treatment of essential hypertension, Kinzalmono was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Danish: Til behandling af essentiel hypertension var Kinzalmono mere effektivt end placebo til at nedsætte det diastoliske blodtryk, og virkningerne af Kinzalmono svarede til virkningerne af andre lægemidler mod forhøjet blodtryk.
English: In the prevention of cardiovascular problems, Kinzalmono had a similar effect to ramipril, with around 17% of patients dying, being admitted to hospital because of cardiovascular problems, or having a heart attack or stroke.
Danish: Til forebyggelse af kardiovaskulære problemer svarede virkningen af Kinzalmono til virkningen af ramipril, idet ca. 17 % af patienterne døde, blev hospitalsindlagt som følge af kardiovaskulære problemer eller fik et hjerteanfald eller slagtilfælde.
English: If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Danish: Ved utilstrækkelig virkning kan dosis øges til 80 mg, eller Kinzalmono kan anvendes i kombination med et andet lægemiddel for hypertension, for eksempel hydrochlorothiazid.
English: For the full list of all side effects reported with Kinzalmono, see the package leaflet.
Danish: Den fuldstændige liste over indberettede bivirkninger ved Kinzalmono fremgår af indlægssedlen.
English: Side effects with Kinzalmono are not common.
Danish: Normalt er der ikke bivirkninger ved Kinzalmono.
English: What is Kinzalmono?
Danish: Hvad er Kinzalmono?
English: What is Kinzalmono used for?
Danish: Hvad anvendes Kinzalmono til?
English: How has Kinzalmono been studied?
Danish: Hvordan blev Kinzalmono undersøgt?
English: What benefit has Kinzalmono shown during the studies?
Danish: Hvilken fordel viser undersøgelserne, at der er ved Kinzalmono?
English: How is Kinzalmono used?
Danish: Hvordan anvendes Kinzalmono?
English: How does Kinzalmono work?
Danish: Hvordan virker Kinzalmono?
English: The marketing authorisation was renewed on 17 August 2003 and on 17 August 2008.
Danish: Markedsføringstilladelsen blev fornyet den 17. august 2003 og den 17. august 2008.
English: NovoNorm is taken before meals, normally up to 15 minutes before each main meal.
Danish: NovoNorm tages inden måltidet, normalt op til 15 minutter før hvert hovedmåltid.
English: The European Commission granted a marketing authorisation valid throughout the European Union for NovoNorm to Novo Nordisk A/S on 17 August 1998.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for NovoNorm til Novo Nordisk A/S den 17. august 1998.
English: NovoNorm is a medicine that contains the active substance repaglinide.
Danish: NovoNorm er et lægemiddel, der indeholder det aktive stof repaglinid.
English: The raised insulin levels returned to normal after the meal.
Danish: De forhøjede insulinkoncentrationer blev normale igen efter måltidet
English: The full EPAR for NovoNorm is available here.
Danish: Den fuldstændige EPAR for NovoNorm findes her.
English: Other information about NovoNorm:
Danish: Andre oplysninger om NovoNorm:
English: The Committee recommended that NovoNorm be given marketing authorisation.
Danish: Udvalget anbefalede derfor udstedelse af markedsføringstilladelse for NovoNorm.
English: Another study looked at the effect of adding NovoNorm to metformin.
Danish: I en anden undersøgelse så man på virkningen af at føje NovoNorm til metformin.
English: NovoNorm should not be used in people who may be hypersensitive (allergic) to repaglinide or any of the other ingredients.
Danish: NovoNorm bør ikke anvendes af personer, som kan være overfølsomme (allergiske) over for repaglinid eller et af de øvrige indholdsstoffer.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NOVONORM EPAR summary for the public
Danish: EUROPÆISK OFFENTLIG VURDERINGSRAPPORT (EPAR) NOVONORM EPAR - Sammendrag for offentligheden
English: The Committee for Medicinal Products for Human Use (CHMP) decided that NovoNorm's benefits are greater than its risks for the treatment of type 2 diabetes.
Danish: Udvalget for humanmedicinske lægemidler (CHMP) konkluderede, at fordelene ved NovoNorm var større end risiciene ved behandling af type 2- diabetes.
English: In the study where NovoNorm was added to metformin, the effects of the two medicines were at least additive (equivalent to the effects of the two medicines added together).
Danish: I den undersøgelse, hvor NovoNorm blev føjet til metformin, var effekten af de to lægemidler som minimum additiv (svarende til de to lægemidler sammenlagt).
English: NovoNorm has been studied in 45 ‘clinical pharmacology' studies (looking at how the medicine works in the body) and 16 clinical trials (looking at its effects in treating type 2 diabetes patients).
Danish: NovoNorm blev undersøgt i 45 klinisk-farmakologiske undersøgelser (hvor det blev undersøgt, hvordan lægemidlet virker i kroppen) og 16 kliniske undersøgelser (hvor man undersøgte virkningen til behandling af type 2-diabetespatienter).
English: NovoNorm doses may also need to be adjusted when given with some medicines used in heart conditions, and to treat pain, asthma and other conditions.
Danish: Doserne af NovoNorm skal muligvis justeres, når de gives sammen med andre lægemidler, der anvendes til hjertesygdomme, behandling af smerter, astma og andre sygdomstilstande.
English: NovoNorm is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Danish: NovoNorm anvendes til patienter, som har type 2-diabetes (ikke-insulinkrævende diabetes).
English: In all studies, NovoNorm led to a decrease in the level of HbA1c, which showed that blood glucose levels had been controlled to a similar level to that seen with the comparator medicines.
Danish: I alle undersøgelser medførte NovoNorm et fald i HbA1c-niveauet, hvilket tydede på, at blodglukosekoncentrationerne var blevet reguleret til et niveau, der svarede til det, der var iagttaget for de øvrige sammenligningspræparater.
English: What is the risk associated with NovoNorm?
Danish: Hvilken risiko er der forbundet med NovoNorm?
English: The full list of these medicines is available in the Package Leaflet.
Danish: Den fuldstændige liste fremgår af indlægssedlen.
English: The most common side effects with NovoNorm (seen in between 1 and 10 patients in 100) are hypoglycaemia (low blood glucose levels), abdominal (tummy) pain and diarrhoea.
Danish: De hyppigste bivirkninger ved NovoNorm (som optræder hos mellem 1 til 10 patienter ud af 100) er hypoglykæmi (lave blodglukosekoncentrationer, mavesmerter og diarré).
English: For the full list of all side effects reported with NovoNorm, see the Package Leaflet.
Danish: Den fuldstændige liste over alle indberettede bivirkninger ved NovoNorm fremgår af indlægssedlen.
English: NovoNorm helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Danish: NovoNorm får bugspytkirtlen til at producere mere insulin i forbindelse med måltider og anvendes til regulering af type 2-diabetes.
English: Why has NovoNorm been approved?
Danish: Hvorfor blev NovoNorm godkendt?
English: NovoNorm may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Danish: NovoNorm kan også anvendes med metformin (et andet lægemiddel mod diabetes) til type 2diabetespatienter, hvis blodglukosekoncentrationer ikke er reguleret tilfredsstillende med metformin alene.
English: NovoNorm is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Danish: Hvis patienten er skiftet fra et andet lægemiddel mod diabetes, er den anbefalede startdosis 1 mg. NovoNorm anbefales ikke til patienter under 18 år på grund af, at der mangler oplysninger om sikkerhed og virkning for denne aldersgruppe.
English: NovoNorm can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Danish: NovoNorm kan også anvendes til type 2-diabetespatienter, hvis blodglukosekoncentrationer normalt reguleres tilfredsstillende med diæt, men hvor blodglukosekoncentrationen midlertidigt er ude af kontrol.
English: What is NovoNorm?
Danish: Hvad er NovoNorm?
English: What benefit has NovoNorm shown during the studies?
Danish: Hvilke fordele viser undersøgelserne, der er ved NovoNorm?
English: What is NovoNorm used for?
Danish: Hvad anvendes NovoNorm til?
English: NovoNorm produced a good insulin response to a meal within 30 minutes of being dosed in type 2 diabetes patients, leading to a blood glucose-lowering effect throughout the meal.
Danish: NovoNorm fremkaldte en tilfredsstillende insulinrespons på et måltid inden for 30 minutter, efter at en dosis var blevet indtaget af patienter med type 2-diabetes.
English: How has NovoNorm been studied?
Danish: Hvordan blev NovoNorm undersøgt?
English: The main studies compared NovoNorm with other medicines used in type 2 diabetes (glibenclamide, glipizide or gliclazide).
Danish: I alt 2 156 patienter fik NovoNorm i alle undersøgelser under et. I hovedundersøgelserne blev NovoNorm sammenlignet med andre lægemidler, som anvendes til type 2-diabetes (glibenclamid, glipizid eller gliclazid).
English: How is NovoNorm used?
Danish: Hvordan anvendes NovoNorm?
English: How does NovoNorm work?
Danish: Hvordan virker NovoNorm?
English: 1070 Brussels Belgium
Danish: 1070 Brussels
English: Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Danish: Bilag I Fortegnelse over lægemidlernes navne, lægemiddelform(er), styrke(r), administrationssvej(e), ansøger(e), indehaver(e) af markedsføringstilladelse(r) i medlemsstaterne
English: D-55216 Ingelheim Germany
Danish: D-55216 Ingelheim
English: Pułaskiego 39 85-619 Bydgoszcz Poland
Danish: 85-619 Bydgoszcz Poland
English: 98 D-82327 Tutzing Germany
Danish: D-82327 Tutzing
English: Défense Ouest 92700 Colombes France
Danish: 92700 Colombes France
English: Alfa Wasserman Pharma SAS 67 rue Anatole France, 92300 Levallois Perret France
Danish: Alfa Wasserman Pharma SAS 67 rue Anatole France, 92300 Levallois Perret
English: TAMIK, capsule soft capsule
Danish: TAMIK, capsule
English: SEGLOR LYOC 5 mg, lyophilisat oral oral lyophilisate
Danish: SEGLOR LYOC 5 mg, lyophilisat oral
English: Arzneimittelvertriebs GmbH, Anton Anderer Platz 6/1, A-1210 Vienna
Danish: WABOSAN Arzneimittelvertriebs GmbH, Anton Anderer Platz 6/1, A-1210 Vienna Austria
English: Acarpia - Servicos Farmaceuticos LDA Rua dos Murcas, 88 Funchal MadeiraPortugal
Danish: Acarpia - Servicos Farmaceuticos LDA Rua dos Murcas, 88
English: UCB PHARMA 420 Avenue Estienne d'Orves
Danish: 420 Avenue Estienne d'Orves Défense Ouest
English: 0.20 g /100 ml oral drops, solution oral use
Danish: 0.20 g /100 ml oral drops, solution oral anvendelse
English: Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna Austria
Danish: Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna
English: Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml oral drops, solution oral use ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Danish: Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml orale dråber, opløsning ratiopharm Arzneimittel Vertriebs-GmbH, Albert-Schweitzer-Gasse 3, A-1140 Vienna Austria
English: IKARAN L.P. 5 mg, comprimé à libération prolongée prolonged-release tablet
Danish: 5 mg, comprimé à libération prolongée
English: SEGLOR 5 mg, gélule 5 mg hard capsule
Danish: SEGLOR 5 mg, gélule 5 mg
English: DHE "ratiopharm" 2,5 mg - Kapseln prolonged-release capsule, hard ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Danish: DHE "ratiopharm" 2,5 mg - Kapseln ratiopharm Arzneimittel Vertriebs-GmbH, Albert-Schweitzer-Gasse 3, A-1140 Vienna Austria
English: LEK farmacevtska družba d.d., Verovskova 57, SI-1526 Ljubljana, Slovenia
Danish: LEK farmacevtska družba d.d., Verovskova 57,
English: Boehringer Ingelheim Pharma GmbH & Co.KG Binger Str. 173
Danish: Boehringer Ingelheim Pharma GmbH & Co.KG
English: modifiedreleasecapsule, hard
Danish: Kapsel med modificeret udløsning, hård
English: 45, PLACE ABEL GANCE F 92654 BOULOGNE CEDEX
Danish: Pierre Fabre Médicaments 45, PLACE ABEL GANCE F 92654 BOULOGNE CEDEX France
English: Dihydroergotaminum Filofarm2 mg/g oral solution
Danish: Dihydroergotaminum Filofarm2 mg/g
English: DHE "ratiopharm" 5 mg - Kapseln prolonged-release capsule, hard
Danish: DHE "ratiopharm" 5 mg - Kapseln
English: Laboratórios AzevedosIndústria Farmacêutica, S.A. PRT
Danish: Laboratórios Azevedos - Indústria Farmacêutica, S.A. PRT Edifícios Azevedos - Estrada Nacional 117
English: Ergovasan 5 mg retard - Kapseln prolonged-release capsule, hard
Danish: Ergovasan 5 mg retard - Kapseln
English: Ergovasan 2,5 mg retard - Kapseln prolonged-release capsule, hard
Danish: Ergovasan 2,5 mg retard - Kapseln
English: Luxembourg Pierre Fabre Médicaments
Danish: UCB PHARMA